Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D study)

CAMH Research Registry Details

What is the purpose of the study?
To discover how personal biomarkers (Genes, proteins, Brain activity) can predict treatment outcomes in patients with clinical depression. To integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

• Individuals with Major Depressive Disorder; Depression

Age range: 18 - 65
Gender: All
Ethnicity: All

What does the study involve?

• Number of contacts: 9 study visits for participants with depression, 4 study visits for participants without depression
• Time period: 12 weeks for participants with depression, 8 weeks for participants without depression
• Length of contacts: 1 - 6 hours 
• Treatment offered: Yes

Study Location(s):
100 Stokes St. (Queen site
1025 Queen St. W, Nicotine Dependence Service

Investigator(s): Dr. Stefan Kloiber

Contact Information:

• Phone: 416-535-8501 ext.31591
• E-mail: optimumd@camh.ca
• Recruitment Flyer Link

Study End Date: 30 April, 2029
REB number: 119/2021
Full Study Title: OPTIMUM-D: Optimized Predictive Treatment In Medications for Unipolar Major Depression

PLEASE NOTE:

• Research staff cannot give medical advice over the phone.
• If you have specific questions regarding your health care, please contact your family physician.
• We regret that not everyone screened for a study will be eligible to participate
• For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.